Company: BIVIW
Filing Date: 2025-08-04
Form Type: S-1/A
Source: 0001520138-25-000235
Chunk: 4

Company: BIOVIE INC.
Filing Date: 2025-08-04
Form: S-1/A
Chunk 4
---
. See “Risk Factors” beginning on page 10.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

|                                                  |     | Per Unit |     | Per             
 Pre-funded Unit |     | Total |
|:-------------------------------------------------|:----|:---------|:----|:----------------|:----|:------|
| Public offering price                            |     | $        |     | $               |     | $     |
| Underwriting discounts and commissions (7.0%)(1) |     | $        |     | $               |     | $     |
| Proceeds, before expenses, to us                 |     | $        |     | $               |     | $     |

| (1) | We refer you to “Underwriting” beginning on page 10 for          
 additional information regarding the underwriters’ compensation. |

We have granted a 45-day option to the underwriters
to purchase up to 298,013 additional shares of Common Stock and/or up to 298,013 additional Pre-funded Warrants and/or
up to 298,013 additional Warrants, or any combination thereof, solely to cover over-allotments, if any.

The underwriters expect to deliver the shares
to purchasers on or about , 2025.

<div align='center'>ThinkEquity

The date of this prospectus is ,
2025

Table of Contents</div>

| About This Prospectus                                                                 |   1 |
| Prospectus Summary                                                                    |   2 |
| The Offering                                                                          |   8 |
| Risk Factors                                                                          |  10 |
| Cautionary Note Regarding Forward-Looking Statements                                  |  35 |
| Use of Proceeds                                                                       |  37 |
| Dividend Policy                                                                       |  38 |
| Capitalization                                                                        |  39 |
| Dilution                                                                              |  40 |
| Securities Market Information                                                         |  42 |
| Business                                                                              |  43 |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations |  53 |
| Management                                                                            |  61 |
| Executive Compensation                                                                |  66 |
| Certain Relationships and Related Party Transactions                                  |  71 |
| Principal Stockholders                                                                |  72 |
| Description of Securities                                                             |  74 |
| Underwriting                                                                          |  79 |
| Legal Matters                                                                         |